SCHEMBL2670677

SCHEMBL2670677

COc1[c]c(F)cc2c(=O)c(C(=O)O)cn([C@@H]3C[C@@H]3F)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.45
KDM4E B2RXH2 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.43
TOP2A P11388 5/20 0.40
TOP2B Q02880 5/20 0.40
KCNH2 Q12809 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
POLB P06746 1/20 0.40
PRKD3 O94806 1/20 0.40
ALOX15 P16050 1/20 0.40
OPRM1 P35372 1/20 0.40
CLK2 P49760 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GSK3B P49841 1/20 0.39
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5235241 1.00 CYP3A4 (0.45) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL2670399 0.87 KDM4E (0.39) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL5618873 0.87 KDM4E (0.39) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL2670277 0.87 TOP2A (0.53) KDM4ESMN1; SMN2CYP1A2TOP2ATOP2B
SCHEMBL2670517 0.85 KDM4E (0.45) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL5618273 0.85 KDM4E (0.45) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL5619845 0.83 KDM4E (0.42) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL2670627 0.83 KDM4E (0.42) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL5619575 0.81 CYP3A4 (0.52) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A
SCHEMBL2670237 0.81 CYP3A4 (0.52) CYP3A4KDM4ESMN1; SMN2CYP1A2TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US claimed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 CYP3A4 153/4885KDM4E 1244/4885SMN1; SMN2 3878/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 CYP3A4 153/4885KDM4E 1244/4885SMN1; SMN2 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.